摘要
目的评价CYP3A5基因多态性与肾移植受者西罗莫司的血药浓度与每千克体质量剂量比值(C0/D)的相关性。方法检索相关数据库,收集CYP3A5基因多态性与肾移植受者西罗莫司C0/D的相关性研究,对纳入文献提取有效数据后应用Rev Man5.3软件进行Meta分析,得出合并后的OR值及95%CI。结果共纳入5篇文献,合计466例患者。Meta分析结果表明,CYP3A5*3/*3基因型的西罗莫司C0/D显著高于CYP3A5*1/*1和CYP3A5*1/*3基因型(P<0.000 01)。结论 CYP3A5基因多态性与肾移植患者术后西罗莫司用药安全性和有效性密切相关,应根据CYP3A5基因型做到个性化给药。
Objective To assess the relationship between CYP3A5 gene polymorphism and the dose ratio of blood drug concentration and body weight（ C0/ D） of sirolimus in renal transplant recipients. Methods Relevant databases were retrieved to collect information about studies on the correlation between CYP3A5 gene polymorphism and sirolimus C0/ D in renal transplant recipients,Meta software Rev Man5. 3 was used to analyze the effective data of the included literature to get the combined OR and 95% CI. Results A total of 5 articles were included involviong466 patients. Meta analysis results showed that the CYP3A5 ＊ 3 / ＊ 3 genotype sirolimus C0/ D was significantly higher than that in CYP3A5＊ 1 / ＊ 1 and CYP3A5＊ 1 / ＊ 3 genotype（ P〈0. 000 01）. Conclusion CYP3A5 gene polymorphism is closely related to the safety and effectiveness of sirolimus in reneal transplantation patients. Individual administration should be based on CYP3A5 genotype.
出处
《解放军药学学报》
CAS
CSCD
2016年第1期66-68,共3页
Pharmaceutical Journal of Chinese People's Liberation Army
